Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Short Interest Up 418.6% in May

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 413,714 shares, an increase of 418.6% from the April 30th total of 79,768 shares. Based on an average daily volume of 1,160,884 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CLPBY shares. Sanford C. Bernstein raised shares of Coloplast A/S to a “hold” rating in a research note on Wednesday, January 28th. The Goldman Sachs Group cut shares of Coloplast A/S from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. Finally, Kepler Capital Markets upgraded shares of Coloplast A/S to a “strong-buy” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Coloplast A/S Trading Down 2.8%

Shares of CLPBY traded down $0.18 during midday trading on Thursday, reaching $6.20. The company had a trading volume of 28,664 shares, compared to its average volume of 571,895. Coloplast A/S has a 1-year low of $6.10 and a 1-year high of $10.03. The company has a quick ratio of 0.81, a current ratio of 1.30 and a debt-to-equity ratio of 1.50. The firm has a 50 day simple moving average of $6.56 and a 200-day simple moving average of $7.75. The stock has a market cap of $13.97 billion, a PE ratio of 44.29, a price-to-earnings-growth ratio of 1.99 and a beta of 0.15.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.01. Coloplast A/S had a net margin of 7.46% and a return on equity of 31.96%. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Research analysts forecast that Coloplast A/S will post 0.4 EPS for the current fiscal year.

About Coloplast A/S

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.